DEFM14A: ATAI to Acquire Beckley Psytech, Redomicile to Delaware

ATAI Life Sciences N.V. proposes to acquire Beckley Psytech Limited and redomicile to Delaware, aiming to enhance its psychedelic-based mental health pipeline and streamline corporate structure.

Summary

• ATAI Life Sciences N.V. (ATAI) plans to acquire the remaining issued share capital of Beckley Psytech Limited (Beckley Psytech) not already owned by ATAI, issuing 105,044,902 ordinary shares as consideration.
• The share issuance for the acquisition is expected to represent approximately 49.5% of ATAI's outstanding ordinary shares prior to the transaction, requiring shareholder approval under Nasdaq rules.
• ATAI also intends to redomicile from the Netherlands to Delaware, USA, through a two-step merger with atai Life Sciences Luxembourg S.A. (atai LuxCo) and subsequent conversion to atai Delaware.
• The redomiciliation aims to simplify the corporate structure, gain operational and cost efficiencies, increase alignment with U.S. operations, and benefit from Delaware's corporate law predictability.
• Beckley Psytech recently announced positive topline Phase 2b clinical trial data for BPL-003 in treatment-resistant depression (TRD), meeting its primary and all key secondary endpoints.
• A single 12 mg dose of BPL-003 showed an 11.1-point reduction in MADRS score at Day 29 (p=0.0038), while an 8 mg dose showed a 12.1-point reduction (p=0.0025) compared to control.
• The average time to meet readiness for discharge criteria for BPL-003 was within two hours of dosing, supporting its potential fit within existing interventional psychiatry treatment paradigms.
• ATAI will issue 101,500,689 ordinary shares and 10,199,886 restricted stock units as preliminary estimated purchase consideration, valued at approximately $523.2 million based on ATAI's closing price of $4.52 on September 3, 2025.
• Beckley Psytech reported a net loss of 22,469 thousand GBP (approximately $28,713 thousand USD) for the year ended December 31, 2024, and had cash and cash equivalents of 5,082 thousand GBP (approximately $5,082 thousand USD) as of that date.
• The acquisition is expected to be accounted for using the asset acquisition method, with substantially all fair value concentrated in an in-process research and development (IPR&D) asset, and no goodwill recognized.
• The redomiciliation is expected to be tax-neutral for ATAI and its shareholders for Dutch and Luxembourg tax purposes, with U.S. federal income tax implications depending on individual shareholder circumstances.

Sentiment

Score: 7

Explanation: The strategic acquisition of a promising asset with positive clinical data, combined with a corporate redomiciliation for efficiency, presents a strong positive outlook despite inherent integration and financing risks. The clinical success of BPL-003 is a significant de-risking event.

Positives

• The acquisition creates a synergistic, fully owned pipeline with proprietary, rapid-acting psychedelic compounds, enhancing ATAI's position in mental health treatment.
• The combined group is expected to accelerate development and improve fundraising capabilities, driving long-term shareholder value and patient innovation.
• Significant pre-tax synergies are anticipated from the integration of ATAI and Beckley Psytech, along with complementary discovery engines.
• Positive topline Phase 2b clinical trial results for BPL-003 in TRD demonstrate rapid, robust, and durable antidepressant effects, supporting advancement to Phase 3.
• The redomiciliation to Delaware is expected to simplify corporate structure, streamline reporting, and enhance operational and financial flexibility.
• Moving to Delaware aligns ATAI with its U.S. listing and significant shareholder base, potentially expanding its investor base and benefiting from established corporate governance principles.
• The Board unanimously recommends voting FOR all proposals, indicating strong internal support for the strategic direction.

Negatives

• The issuance of 105,044,902 ordinary shares for the acquisition will result in significant dilution, representing approximately 49.5% of ATAI's outstanding shares prior to the transaction.
• Beckley Psytech has a limited operating history, no revenues to date, and has incurred net losses since inception, with expectations of continued losses in the short to medium term.
• The combined group will require substantial additional financing in the future to fund costly and time-consuming clinical trials and operations.
• There are significant transaction costs associated with the acquisition and redomiciliation, many of which will be borne by ATAI even if the acquisition is not completed.
• Integration of the two businesses presents challenges, including potential loss of key personnel, disruption of operations, and unforeseen expenses.
• The redomiciliation may result in adverse tax consequences for certain U.S. Holders, particularly those with significant ownership or who have not made specific tax elections.

Risks

• The number of ordinary shares issued for the acquisition is fixed and will not adjust for changes in ATAI's trading price, potentially leading to greater dilution if the price increases.
• Failure to complete the acquisition could negatively impact ATAI's share price and require payment of termination fees of $4 million or $10 million.
• Completion of the acquisition is subject to shareholder approval and satisfaction of the Warranty Condition, which may not be fulfilled in a timely manner or at all.
• The combined group may fail to realize the anticipated benefits and synergies of the acquisition, or the cost to achieve them may be higher than expected.
• Clinical trials are inherently uncertain, and BPL-003's preliminary or early-stage results may not be predictive of final outcomes or lead to regulatory approval.
• The combined group will incur losses for the foreseeable future and might never achieve profitability, requiring additional financing that may not be available on favorable terms or at all.
• The redomiciliation's expected benefits may not be realized, and the Board may delay or abandon it at any time prior to its effectiveness.
• The LuxCo Merger triggers withdrawal rights for dissenting ATAI shareholders, potentially impacting cash position if aggregate cash compensation exceeds $5 million.
• Changes in law, policy, or practice may result in adverse tax consequences for ATAI and its shareholders in relation to the redomiciliation.
• The redomiciliation may adversely affect the trading, liquidity, and price of ATAI shares, as some shareholders may not wish to hold shares of a Delaware issuer.
• The combined group must maintain effective internal controls over financial reporting, and failure to do so could adversely affect financial reporting and share price.
• Future sales of ordinary shares, including those issued in the acquisition and those subject to registration rights, could negatively impact the market price of ordinary shares.

Future Outlook

The combined group is expected to accelerate development and raise required funding, driving long-term value for shareholders and delivering meaningful innovation for patients. ATAI and Beckley Psytech plan to engage with the U.S. Food and Drug Administration (FDA) regarding the Phase 3 trial design for BPL-003 in TRD in the coming months. Data from the BPL-003 open-label extension (OLE) study is expected in the third quarter of 2025, providing additional insights into safety, tolerability of repeat dosing, and durability of antidepressant effect. The redomiciliation is anticipated to enhance shareholder value by simplifying the corporate structure, streamlining reporting requirements, increasing alignment with U.S. operations, and benefiting from the predictability and flexibility of Delaware law.

Management Comments

• The Board unanimously recommends that ATAI shareholders vote FOR each of the Acquisition Proposal, the Share Issuance Proposal, the Director Nominee Proposals, the Governing Documents Proposal, the Redomiciliation Proposal, the Redomiciliation Withdrawal Rights Proposal and the Redomiciliation Share Conversion Proposal.
• We believe the Redomiciliation will enhance shareholder value over the long-term by simplifying the corporate structure to gain operational and cost efficiencies.

Industry Context

ATAI Life Sciences operates in the highly competitive biopharmaceutical industry, specifically focusing on psychedelic-based treatments for mental health conditions. The acquisition of Beckley Psytech, a clinical-stage company with a proprietary pipeline, positions the combined entity to strengthen its market presence and accelerate development in this emerging therapeutic area. The industry is characterized by significant R&D investment, complex regulatory pathways, and a high unmet medical need for effective mental health treatments. The move to Delaware aims to align ATAI with the U.S. market, where many of its competitors and investors are based, potentially improving its competitive standing and access to capital.

Comparison to Industry Standards

• BPL-003's rapid-acting profile and short time-in-clinic (approximately two hours) support its potential to fit within the existing interventional psychiatry treatment paradigm established by Spravato (esketamine nasal spray), an FDA-approved medication for TRD.
• Beckley Psytech faces competition in TRD from companies like Freedom Biosciences, Supernus Pharmaceuticals, Inc., GH Research PLC, and Compass Pathways PLC.
• For Alcohol Use Disorder (AUD), potential competitors include Adial Pharmaceuticals Inc., Alkermes PLC, and Indivior PLC, in addition to existing FDA-approved medications like disulfiram, acamprosate, and naltrexone.

Management Changes

Corporate Governance

Legal Proceedings

• No material outstanding litigation related to Beckley Psytech.
• ATAI is currently the defendant in ongoing litigation with DemeRx.

Related Party Transactions

• Apeiron Investment Group Ltd., an entity affiliated with Chairman Christian Angermayer, is a significant shareholder (approximately 23.6% of outstanding Ordinary Shares pre-PIPE Financings).
• Apeiron entered into a Shareholders Rights Agreement, granting it the right to select director designees to the Board based on ownership thresholds (two designees for >=12.5% equity, one for >=7.5% but <12.5%).
• Apeiron also entered into a Lock-Up Agreement, restricting the transfer of its equity securities for a specified Lock-Up Period.
• Christian Angermayer was granted options to purchase 337,686 and 292,500 Ordinary Shares, vesting based on continued service and achievement of asset value goals by December 31, 2026.
• Apeiron participated in the July PIPE Financing.
• ATAI entered into a senior promissory note to advance up to $10.0 million to Beckley Psytech, which is a related party transaction given ATAI's existing investment.
• Beckley Psytech made payments of 0.03 million GBP to the Beckley Foundation (an associated charity) in 2024 and 2023 for a payment license, with future royalty payments of 1% of net revenues committed once revenue-generating.

Stakeholder Impact

• Shareholders: Will experience dilution from the acquisition's share issuance but may benefit from a strengthened pipeline and potential synergies. Redomiciliation will alter shareholder rights under Delaware law. Dissenting shareholders have withdrawal rights during redomiciliation.
• Employees: Beckley Psytech employees will become part of the combined group. Key personnel of Beckley Psytech may leave, impacting integration. Robert Conley is expected to be employed as Chief Research and Development Officer of ATAI.
• Customers/Patients: The combined group aims to deliver meaningful innovation for patients by accelerating the development of psychedelic-based mental health treatments.
• Creditors: The redomiciliation process includes a creditor opposition period, and the company believes its financial position post-merger will provide no less safeguards for creditors' claims.
• Suppliers: Integration could result in the loss of suppliers or disruption of existing business relationships.

Next Steps

• Hold an Extraordinary General Meeting on November 4, 2025, for shareholder votes on the acquisition, share issuance, director appointments, name change, and redomiciliation proposals.
• Engage with the U.S. Food and Drug Administration (FDA) regarding the Phase 3 trial design for BPL-003 in TRD.
• Expect data from the BPL-003 open-label extension (OLE) study in the third quarter of 2025.
• Complete the Beckley Carve-Out, reorganizing Eleusis and its subsidiaries out of the Beckley Group prior to the acquisition closing.
• Effectuate the redomiciliation to Delaware, involving a merger with atai LuxCo and subsequent conversion to atai Delaware, expected before the end of 2025.

Key Dates

Recommendation

The acquisition of Beckley Psytech, particularly following the positive Phase 2b clinical trial results for BPL-003 in Treatment-Resistant Depression, represents a significant strategic enhancement to ATAI's pipeline. This strengthens the company's position in the rapidly evolving psychedelic-based mental health treatment market. The planned redomiciliation to Delaware is a sound move to improve operational efficiencies, align with the U.S. investor base, and benefit from a more predictable corporate governance framework. While there is dilution from the share issuance and inherent risks in drug development and integration, the clinical validation of BPL-003 and the strategic rationale for the combined entity suggest substantial long-term value creation potential. The current market price of $4.95 (as of Sept 19, 2025) compared to analyst targets of $5.00-$11.00 indicates potential upside.

Keywords

atai Life Sciences, Beckley Psytech, acquisition, redomiciliation, biopharmaceutical, mental health, psychedelic, BPL-003, TRD, Delaware, corporate governance, SEC filing, Nasdaq, clinical-stage, drug development